AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAY 9 - (NewsRx.com & NewsRx.net) --
Researchers in Italy report that a triple course of hepatitis B vaccination is not effective in preventing infection in patients who have undergone liver transplantation for hepatitis-B-related cirrhosis.
Gastroenterologist M. Angelico and colleagues at the University of Rome Tor Vergata reported their findings at the 36th annual meeting of the European Association for the Study of the Liver (EASL), held April 18-22, 2001, in Prague, Czech Republic. Their study is titled "Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis."
Angelico et al. wrote in their EASL conference abstract: "Long-term immunoprophylaxis with HBIG is used to prevent HBV [hepatitis B virus] reinfection after liver transplantation for HBV-related cirrhosis. This approach is highly expensive. A recent report proposed post-transplant HBV vaccination with a reinforced schedule as an alternative strategy, perhaps allowing permanent HBIG discontinuation.
"We investigated the efficacy of a reinforced triple course of HBV vaccination in 17 patients transplanted for HBsAg positive cirrhosis two to seven years earlier. The first cycle consisted of three double i.m. [intramuscular] doses (40 g) of recombinant vaccine at month 0, 1 and 2, respectively. This was followed, in non responders, by a second cycle of six intradermal 10 g doses every 15 days (the intradermal route is ...
Source: HighBeam Research, New Approach Needed To Prevent Hepatitis B In Patients.(Brief Article)